Answers are grounded in this paper and cite their sources.
Background: Although β-arrestin-2 (β-arr2) and CXCR2 have been shown to affect various malignant tumors, their exact roles in lung cancer remain unclear.We investigated expression of β-arr2 and CXCR2 in patients with non-small cell lung cancer (NSCLC) and their correlation with lymph node metastasis and prognosis.Methods: We reviewed medical records of 136 patients with NSCLC who underwent surgical resection, and assessed their specimens immunohistochemically for expression of β-arr2 and CXCR2 in primary tumors and metastatic lymph nodes (MLNs), respectively.Results: High β-arr2 expression was seen in 63 specimens (46.3%), and was significantly associated with male patients (P=0.011),squamous cell carcinoma (P=0.003), and lymph node metastasis (P<0.001).High CXCR2 expression was seen in 62 specimens (45.6%), and was significantly correlated only with lymph node metastasis (P<0.001).Expression of β-arr2 was significantly lower at MLNs than at primary lesions (Z=-2.315;P=0.021; Wilcoxon signed-rank), whereas CXCR2 expression was significantly higher in MLNs than in primary lesions (Z=-3.712;P<0.001; Wilcoxon signed-rank).No relationship was seen between β-arr2 and CXCR2 expression in primary lesions (r=-0.065,P=0.548; Spearman rank coefficient), but they were inversely related in MLNs (r=-0.263,P=0.012).Kaplan-Meier survival curve was shown that low β-arr2 and high CXCR2 expressions was associated with poor survival (log-rank: χ 2 =5.926,P=0.015).Conclusions: β-arr2 may promote lymph node metastasis in NSCLC by modulating CXCR2 activation.
No takes yet. Share an insight, caveat, or question.
Qiu et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: